ArticleFrontiers in oncology2021
Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study.
Min Yuan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
25 papers cite it
this paperpooled ittrialcites it